Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe.

Beckman Coulter continues to pay attention to the development of the coagulation market, and recently launched a strategic cooperation with Accurdx in the field of intelligent coagulation, setting another milestone in localization innovation.

Dublin-based diagnostics firm Trinity Biotech on Thursday reported a 61 percent year-over-year increase in second quarter revenues, driven in part by sales of its PCR viral transport media for SARS-CoV-2 testing.

The Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval to the Thermo Fisher Scientific's Oncomine Dx Target Test to be used as a companion diagnostic to identify patients with RET-fusion positive non-small cell lung cancer (NSCLC).

On September 13, 2021, Shanghai Labway Medical Laboratory Co., Ltd. was listed on Shenzhen Stock Exchange (SZSE) ChiNext. Stock code: 688622. The number of new shares publicly issued this time is 48.062 million shares, the issue price is CNY4.17/share, and the opening price is CNY18.25/share.

On September 13, 2021, Guangzhou Hexin Instrument Co., Ltd. was listed on SSE STAR Market. Stock code: 688622. The number of A shares publicly issued this time is 17.5 million shares, the issue price is CNY 17.7/share, and the opening price is CNY 92.11 /share.

Life science company RareCyte said on Thursday that it completed $24 million in financing from both new and existing investors.

PerkinElmer said on Wednesday that it has priced an offering of senior notes totaling $2.3 billion, providing the company with funds to help complete its planned acquisition of BioLegend.

Siemens Healthineers on Thursday announced a collaboration with A1 Life Sciences to offer an evolving portfolio of PCR-based assays for the identification of SARS-CoV-2 mutations and variants.

Roche announced on Thursday that it has entered a share purchase agreement to acquire 100 percent of the outstanding shares of the TIB Molbiol Group.